Lipid microsphere-coated PGE1 improves peritoneal transport and reduces inflammation in peritoneal dialysis: A randomized clinical pilot trial.

Abstract

OBJECTIVE:

To evaluate the effects of lipid microspheres coated with prostaglandin E1 (lipo-PGE1) on peritoneal transport function and inflammation in patients with end-stage renal disease undergoing continuous ambulatory peritoneal dialysis (CAPD).

METHODS:

In total, 89 patients were randomly allocated to the lipo-PGE1 and control groups. All the patients received conventional treatment, and those in the lipo-PGE1 group received lipo-PGE1 intravenously for 2 weeks. The levels of β2-microglobulin (β2-MG), cystatin C, albumin, urea, creatinine, interleukin-6 (IL-6), matrix metalloproteinase-2 (MMP-2), and high-sensitivity C-reactive protein (hs-CRP) were measured before and at 1 and 2 weeks after treatment.

RESULTS:

In the lipo-PGE1 group, the peritoneal clearance rates of β2-MG, cystatin C, and albumin were significantly increased comparing with pre-treatment values, and the IL-6 appearance rate (AR) in the peritoneal dialysate and the serum levels of IL-6 and hs-CRP were markedly decreased (p < 0.05). The lipo-PGE1 group had significantly higher peritoneal clearance rates of β2-MG and cystatin C and lower IL-6 AR in the peritoneal dialysate than the control group (p < 0.05).

CONCLUSIONS:

Lipid microspheres coated with prostaglandin E1 may increase the peritoneal clearance of moderately sized molecules and macromolecules with insignificant effect on the clearance of small molecules. The reduction in IL-6 level following treatment with lipo-PGE1 may alleviate inflammation.

• Authors: Jianwen Wang, Shiqi Tang, Yang Xie, Jun Liu, Jishi Liu, Hong Wu, Hao Zhang
• Journal: Seminars in dialysis (Semin Dial) Vol. 34 Issue 3 Pg. 235-244 (05 2021) ISSN: 1525-139X [Electronic] United States
• PMID: 33592131 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: © 2021 Wiley Periodicals LLC.

Chemical References

• Lipids
• Matrix Metalloproteinase 2
• Alprostadil

Topics

• Alprostadil (therapeutic use)
• Humans
• Inflammation (etiology)
• Lipids
• Matrix Metalloproteinase 2
• Microspheres
• Peritoneal Dialysis (adverse effects)
• Pilot Projects
• Renal Dialysis